Related Experiment Video
Updated: Oct 3, 2026

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
Published on: June 2, 2023
Synergistic inhibitory activity of alpha- and beta-LFA-1 peptides on LFA-1/ICAM-1 interaction
H Yusuf-Makagiansar1, I T Makagiansar, Y Hu
1Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66047, USA.
Insights
This study reveals that peptide LBE enhances the binding of peptide cLAB.L to cells, improving inhibition of T-cell adherence. LBE modifies ICAM-1 conformation, suggesting a distinct binding site for enhanced LFA-1/ICAM-1 interaction blocking.
Area of Science:
- Immunology
- Cell Biology
- Biochemistry
Background:
- Leukocyte function-associated antigen 1 (LFA-1) and its ligand intercellular adhesion molecule 1 (ICAM-1) are crucial for immune and inflammatory processes.
- Critical binding residues for LFA-1/ICAM-1 interaction are located in the I-domain of LFA-1's alpha-subunit and the I-like domain of its beta-subunit.
- Previous research identified the cyclic peptide cLAB.L, derived from the LFA-1 I-domain, as an inhibitor of LFA-1/ICAM-1 interaction.
Purpose of the Study:
- To investigate the effect of the I-like domain peptide LBE on the binding mechanism of the LFA-1 inhibitor cLAB.L.
- To elucidate the roles of LBE and cLAB.L in modulating LFA-1/ICAM-1 interactions and T-cell adherence.
- To understand how LBE influences ICAM-1 conformation and its subsequent binding with cLAB.L.
Main Methods:
- Utilized T-cells and epithelial cells to study cell adhesion.
- Administered peptides cLAB.L and LBE in varying sequences to assess their impact on cell adherence.
- Analyzed ICAM-1 conformation changes induced by peptide treatment.
Main Results:
- Peptide LBE was found to enhance the binding of peptide cLAB.L to both T-cells and epithelial cells.
- The combined application of LBE and cLAB.L significantly suppressed the adherence of T-cells to epithelial monolayers.
- Pre-treatment of epithelial monolayers with LBE before adding cLAB.L yielded a superior inhibitory effect compared to the reverse order.
- LBE induced conformational changes in ICAM-1, distinct from cLAB.L's binding site, facilitating enhanced cLAB.L binding.
Conclusions:
- Peptide LBE acts synergistically with cLAB.L to inhibit LFA-1/ICAM-1-mediated T-cell adherence.
- LBE's ability to alter ICAM-1 conformation is key to enhancing the inhibitory efficacy of cLAB.L.
- This study provides insights into novel strategies for modulating immune cell interactions through combined peptide therapies targeting LFA-1 and ICAM-1.
Abstract:
Interactions of cell-adhesion molecule LFA-1 and its ligand ICAM-1 play important roles during immune and inflammatory responses. Critical residues of LFA-1 for ICAM-1 binding are known to be in the I-domain of the alpha-subunit and the I-like domain of the beta-subunit. On the basis of our previous work demonstrating the inhibitory activity of I-domain cyclic peptide cLAB.L on LFA-1/ICAM-1 interaction, here we have explored the activity of I-like-domain peptide LBE on the binding mechanism of cLAB.L. LBE enhances cLAB.L binding to T-cells and epithelial cells. The adherence of T-cells to epithelial monolayers was suppressed by the two peptides. The addition of LBE to the monolayers prior to the addition cLAB.L produced a better inhibitory effect than the reverse procedure. LBE, but not cLAB.L, changes the ICAM-1 conformation, suggesting that LBE binds to ICAM-1 at sites that are distinct from these of cLAB.L and induces improved conformation in ICAM-1 for binding to cLAB.L.
Related Concept Videos
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Intracellular Signaling Affects Focal Adhesions
Some...
Inhibitors of Gram-positive Cell Wall Synthesis
